



Artesunate injections as treatment for severe malaria


Practical aspects

Martin De Smet,
Head of MSF's Malaria Working Group


RBM CMWG – Annecy – March 2013

Artesunate injections for severe malaria

- WHO recommended treatment, also for African children & pregnant
- WHO prequalified source available
- relative mortality reduction compared to quinine:
34,7 % in the SEQUAMAT trial and 22,5 % in the AQUAMAT trial
- support material available:



MAKING THE SWITCH
Ensuring access to improved treatment
for severe malaria in Africa



- (4) www.msf.org/msf/articles/2011/04/malaria-making-the-switch.cfm
- (5) www.msfaccess.org/content/meeting-report-saving-more-lives-artesunate-injection

Parenteral artesunate: FAQ's

- AS inj for patients only vomiting ?
- AS inj after pre-referral treatment with AS
- Time interval last injection and oral ACT ?
- Is there flexibility in time schedule ?
- Pre-calculated doses: why often higher ?
- Why should AS be used immediately after preparation?
- Preferred mode IV administration ?
- Can other solutions be used ?
- What if larger or smaller volumes used ?
- Why should IV be administered slowly ?
- Can AS inj solution be given oral (NG tuben,...)?

Prepared by

- *Martin De Smet (MSF)*
- *Prudence Hammade(Malaria Consortium)*

1421 patients treated with AS injections & documented, in 9 MSF projects (1) 2011-2012

| AGE | n |
|---------------|----------|
| 0- 11 months | 310 |
| 12-59 | 892 |
| ≤ 5 y | 209 |
| ? | 9 |
| WEIGHT | n |
| < 5 kg | 63 |
| 5-15 kg | 1157 |
| 16-50 kg | 152 |
| >50 kg | 42 |
| ? | 7 |

| ROUTE | n | % |
|-----------------|----------|----------|
| IV | 1238 | 87,1 |
| IM | 179 | 12,6 |
| IV & IM | 4 | 0,3 |
| DURATION | | |
| < 24 hr | 259 | 18,3 |
| 24 hr | 823 | 58,1 |
| 25-48 hr | 163 | 11,5 |
| 49-72 hr | 76 | 5,4 |
| > 72 hr | 95 | 6,7 |
| ? | 5 | |

(1)DRC, CAR, Niger, S Sudan, Chad, Nigeria, Sierra Leone, Somalia, Guinea-C

NUMBER OF DOSES

| n inj | n patients | % pts |
|--------------|-------------------|--------------|
| 1 | 80 | 5,7 |
| 2 | 178 | 12,6 |
| 3 | 858 | 60,8 |
| 4 | 155 | 11,0 |
| 5 | 64 | 4,5 |
| 6 | 23 | 0,4 |
| 7 | 30 | 2,1 |
| 8 | 19 | 1,3 |
| 9 | 3 | 0,2 |
| 10 | 0 | 0,0 |
| 11 | 1 | 0,1 |

| OUTCOME | | |
|----------------|-----------|--------------|
| CURED | 1265/1350 | 93,7 |
| DIED | 66 /1350 | 4,9 |
| OTHER | 19 /1350 | 1,4 |
| UNKNOWN | 71 /1350 | 5,2 % |

ARTESUNATE INJECTION FOR SEVERE MALARIA

WHO
RECOMMENDED
TREATMENT



PRODUCT DESCRIPTION

Artesunate powder: **60mg** + 1 ampoule sodium bicarbonate + 1 ampoule saline solution.

Dose: 2.4 mg/kg

Can be given by intravenous route (IV) or intramuscular route (IM).
IV is the preferred route of administration.

1 WEIGH THE PATIENT

2 CHECK VIALS NEEDED

| Weight | 5 kg-25 kg | 26-50 kg | 51-75 kg | 76-100 kg |
|------------|------------|----------|----------|-----------|
| 60 mg vial | 1 | 2 | 3 | 4 |

3 RECONSTITUTE

Artesunate powder + bicarbonate ampoule (immediately before use)

A

Artesunate powder + bicarbonate ampoule

B Inject full contents of bicarbonate ampoule into artesunate vial.

C Shake until dissolved. Solution will be cloudy.

D The reconstituted solution will clear in about 1min. Discard if not clear.

4 DILUTE

Volume for dilution

| | IV | IM |
|-----------------------------|-------------|-------------|
| Bicarbonate solution volume | 1 ml | 1 ml |
| Saline solution volume | 5 ml | 2 ml |
| Total volume | 6 ml | 3 ml |

| | | |
|----------------------------------------|----------|----------|
| Artesunate 60mg solution concentration | 10 mg/mL | 20 mg/mL |
|----------------------------------------|----------|----------|

Reconstituted artesunate + saline solution (or dextrose 5%)

A

Artesunate reconstituted + saline solution

B Withdraw all the air from the vial.

C Inject required volume of saline into the reconstituted solution.

D Artesunate solution is now ready for use.

⚠ Water for injection is not an appropriate diluant

5 CALCULATE THE DOSE

Calculate and withdraw the required dose in ml according to route of administration:

| For intravenous route (IV) | For intramuscular route (IM) |
|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| $\frac{2.4 \text{ mg} \times \text{body weight (kg)}}{\text{IV artesunate solution concentration 10 mg/ml}}$ | $\frac{2.4 \text{ mg} \times \text{body weight (kg)}}{\text{IM artesunate solution concentration 20 mg/ml}}$ |
| Round up to the next whole number | Round up to the next whole number |

| Example: | Example: |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Dose needed (ml) for 8 kg child: $\frac{2.4 \times 8}{10} = 1.92\text{ml}$ Round up to 2 ml | Dose needed (ml) for 8 kg child: $\frac{2.4 \times 8}{20} = 0.96\text{ml}$ Round up to 1 ml |

6 ADMINISTER

IV: slow bolus 3-4 ml per minute.

IM: inject slowly. Spread doses of more than 5 milliliters over different sites.

7 DOSING SCHEDULE

Give **3 parenteral doses** for a minimum of 24 hours once started, irrespective of the patient's ability to tolerate oral medications earlier.

- Dose 1: on admission (0 Hours)
- Dose 2: 12 hours later
- Dose 3: 24 hours after first dose

- If the patient can take oral medication, prescribe a full 3-day course of recommended first line oral Artemisinin Combination Therapy (ACT).
- If the patient cannot take oral medication, continue with parenteral treatment (one dose a day), for a maximum of 7 days, until oral medication can be given.

• Evaluate the patient's progress regularly.

IMPORTANT

- Prepare a fresh solution for each administration.
- Discard any unused solution after use.

This job aid is intended to demonstrate to health workers how to prepare and administer injectable Artesunate, a treatment for severe malaria. It is not intended to provide personal medical advice. The responsibility for the interpretation and use of this material lies with the reader. In no event shall MMV be liable for damages arising from its use. © 2012 MMV Medicines for Malaria Venture (MMV). All rights reserved. A copy of this document can only be made upon MMV's written authorization.



Thank you !

martin.de.smet@brussels.msf.org